Previous 10 | Next 10 |
Takeda Pharmaceutical Company Limited (TKPHF) Q4 2019 Earnings Conference Call May 13, 2020, 08:30 AM ET Company Participants Takashi Okubo - IR Christophe Weber - President and CEO Andrew Plump - President of R&D Costa Saroukos - CFO Ramona Sequeira - President of USBU a...
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since t...
SIFCO (NYSEMKT: SIF ) +61% on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2019 Q4 earnings Read more ...
Takeda Pharmaceutical Company Limited (TOKYO: 4502) (NYSE: TAK) (“Takeda”) today announced financial results for the year ended March 31, 2020 (FY2019). As a top 10 global R&D-driven biopharmaceutical company, Takeda is demonstrating its innovation and values in its respon...
Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...
Protalix BioTherapeutics (NYSEMKT: PLX ) announces positive results from a Phase 3 clinical trial, BRIDGE , evaluating enzyme replacement therapy pegunigalsidase alfa (PLX-102) in Fabry disease patients who previously received Takeda's (NYSE: TAK ) Replagal (agalsidase alfa). More news ...
The European Commission has granted Takeda Pharmaceutical (NYSE: TAK ) a Marketing Authorization for the subcutaneous (SC) formulation of Entyvio (vedolizumab), a gut-selective biologic for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC)...
− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − Additional treatment modality provides more options for how pa...
OSAKA, Japan , and KING OF PRUSSIA, Pa. , May 7, 2020 /PRNewswire/ -- The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAVITRI ™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MA...
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK...